Ok, fair enough. I agree there are definitely a lo
Post# of 148174
(Total Views: 525)
Posted On: 01/01/2021 1:21:02 PM
Ok, fair enough. I agree there are definitely a lot of question marks around GvHD...
What I find interesting is this: wouldn't switching from a blinded randomized placebo-controlled design to an open-label design under which all enrollees receive leronlimab - and esp. the FDA agreeing to that change - suggest that it would have been unethical to continue giving placebo, probably or possibly because there were signs of efficacy observed?
What I find interesting is this: wouldn't switching from a blinded randomized placebo-controlled design to an open-label design under which all enrollees receive leronlimab - and esp. the FDA agreeing to that change - suggest that it would have been unethical to continue giving placebo, probably or possibly because there were signs of efficacy observed?
(1)
(0)CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼